Bristol-Myers Squibb stock gained 2.22 percent on pipeline news

Published on 09/28/2026 at 13:10 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Bristol-Myers Squibb stock stood at USD 62.86 on September 25, 2026, as BMS outlined Phase 3 ZENBEXUS data. Q2 revenue reached USD 12.97 billion.

Pharmazeutisches Forschungslabor mit NYC-Skyline, Wissenschaftler bei der Arbeit — Bristol-Myers Squibb US1078421011 zeigt Wissenschaftler in modernem New Yorker Onkologie-Labor mit Stadtpanorama, Illustration mit AI erstellt.

Bristol-Myers Squibb stock gained 2.22 percent to USD 62.86 on the NYSE on September 25, 2026 at 4:00 p.m. ET. The move followed a pipeline update on ZENBEXUS and gives investors two measurable reference points: a market capitalization of USD 128.4 billion and a 52-week range of USD 42.52 to USD 68.64.

ZENBEXUS adds a pipeline catalyst

On September 25, 2026, StockTitan reported that Bristol Myers Squibb had announced the first presentation of results for ZENBEXUS, or iberdomide, combined with daratumumab in the Phase 3 EXCALIBER-RRMM trial. The study concerns patients with relapsed or refractory multiple myeloma, making the update relevant to the company's effort to renew growth beyond mature medicines.

The event is more than a research date because the program sits in a commercial disease area already central to Bristol Myers Squibb's portfolio. The company says its pipeline contained 49 compounds in development across more than 40 disease areas as of July 30, 2026, according to its corporate website.

Q2 revenue beat consensus

Bristol Myers Squibb's Q2 2026 revenue reached USD 12.97 billion, up 5.7 percent year over year, while reported EPS of USD 2.04 exceeded the USD 1.60 consensus estimate by USD 0.44, according to MarketBeat. The earnings report was released on July 30, 2026, so the latest market narrative combines a quantified operating beat with a newer pipeline milestone.

Management's fiscal 2026 EPS guidance stands at USD 6.75 to USD 7.00, while the Q2 revenue figure of USD 12.97 billion was above the USD 11.74 billion consensus estimate. The gap between actual and expected revenue was USD 1.23 billion, a useful counterweight to concerns over product maturity and future patent pressure.

Stock remains below its yearly high

The September 25 price of USD 62.86 stood USD 5.78 below the 52-week high of USD 68.64 and USD 20.34 above the low of USD 42.52. Trading volume reached 10,032,444 shares, while the latest quarterly dividend was USD 0.63 per share, payable November 2, 2026 to shareholders of record October 2, 2026, as Business Wire reported.

For investors, the next scheduled checkpoint is Bristol Myers Squibb's Q3 2026 report on October 29, 2026, according to StockTitan. That release should show whether the Q2 revenue growth and pipeline progress are translating into continued execution.